POBA vs BMS

64
Interventional Conference Bare Metal Stents

Transcript of POBA vs BMS

Page 1: POBA vs  BMS

Interventional Conference

Bare Metal Stents

Page 2: POBA vs  BMS

Basic Stent Design

Page 3: POBA vs  BMS
Page 4: POBA vs  BMS
Page 5: POBA vs  BMS
Page 6: POBA vs  BMS
Page 7: POBA vs  BMS
Page 8: POBA vs  BMS

Closed Cell design

Modular Cell design

Page 9: POBA vs  BMS
Page 10: POBA vs  BMS
Page 11: POBA vs  BMS
Page 12: POBA vs  BMS
Page 13: POBA vs  BMS
Page 14: POBA vs  BMS
Page 15: POBA vs  BMS
Page 16: POBA vs  BMS
Page 17: POBA vs  BMS

High Pressure Inflation must balance vessel injury vs. stent approximation

Page 18: POBA vs  BMS
Page 19: POBA vs  BMS

POBA vs BMS

Page 20: POBA vs  BMS
Page 21: POBA vs  BMS
Page 22: POBA vs  BMS
Page 23: POBA vs  BMS
Page 24: POBA vs  BMS
Page 25: POBA vs  BMS
Page 26: POBA vs  BMS
Page 27: POBA vs  BMS
Page 28: POBA vs  BMS
Page 29: POBA vs  BMS
Page 30: POBA vs  BMS
Page 31: POBA vs  BMS

> 3 mm

< 3 mm

Page 32: POBA vs  BMS
Page 33: POBA vs  BMS
Page 34: POBA vs  BMS
Page 35: POBA vs  BMS

No difference in small vessels PTCA vs. Stent

Page 36: POBA vs  BMS

Non benefit for BMS in small vessels

Page 37: POBA vs  BMS
Page 38: POBA vs  BMS
Page 39: POBA vs  BMS
Page 40: POBA vs  BMS
Page 41: POBA vs  BMS
Page 42: POBA vs  BMS
Page 43: POBA vs  BMS

BMS in Acute MI

Page 44: POBA vs  BMS
Page 45: POBA vs  BMS
Page 46: POBA vs  BMS
Page 47: POBA vs  BMS

CABG vs. Stent

Page 48: POBA vs  BMS
Page 49: POBA vs  BMS
Page 50: POBA vs  BMS
Page 51: POBA vs  BMS
Page 52: POBA vs  BMS
Page 53: POBA vs  BMS
Page 54: POBA vs  BMS
Page 55: POBA vs  BMS
Page 56: POBA vs  BMS

BMS in SVG

Page 57: POBA vs  BMS

Saved• Description

Stenting vs. PTCA for angiographic restenosis in vein grafts.

• HypothesisTo compare stent implantation with balloon angioplasty for the treatment of obstructive disease of venous bypass grafts.

• Drugs/Procedures UsedPalmaz-Schatz coronary stent vs balloon angioplasty

• Concomitant Medications

• Patients assigned to stent placement received aspirin (325 mg qd) and dipyridamole (75 mg tid), beginning at least 24 hours before the procedure.

• During the procedure, patients received intravenous dextran 40 and heparin to maintain an activated clotting time of more than 300 seconds. Warfarin therapy was begun on the day of the procedure, and heparin therapy was continued until a therapeutic prothrombin time (international normalized ratio, 2.0 to 3.5) was achieved.

• Dipyridamole and warfarin were continued for one month, and aspirin indefinitely.

Page 58: POBA vs  BMS
Page 59: POBA vs  BMS
Page 60: POBA vs  BMS

Use of Covered stent

Page 61: POBA vs  BMS
Page 62: POBA vs  BMS

Covered Jo stent in SVG

Page 63: POBA vs  BMS

DES vs. BMS

Page 64: POBA vs  BMS